Treatment of pancreatic adenocarcinoma with the combinationof carboplatin and velparib

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-003785-24-HU

Enrollment

Unknown

Registered

2014-09-12

Start date

2014-10-02

Completion date

Unknown

Last updated

2017-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic adenocarcinoma MedDRA version: 17.0 Level: LLT Classification code 10033611 Term: Pancreatic carcinoma non-resectable System Organ Class: 100000004864

Interventions

Product Name: Veliparib 40 mg Product Code: ABT-888 Pharmaceutical Form: Capsule INN or Proposed INN: Veliparib CAS Number: 912444-00-9 Current Sponsor code: ABT-888 Other descriptive name: VELIPARIB

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: inoperable pancretaic adenocarcinoma with ATM-P604S mutation Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 1 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: operable pancreas tumor at the screening CT

Design outcomes

Primary

Measure	Time frame
Main Objective: Patient has inoperable pancretaic adenocarcinoma with ATM-P604S mutation. In case of alteration of ATM tumor suppressor gene, PARP inhibitors can be suitable for treatment. The aim of the treatment to shrink the tumor in order to make it removeable. ;Secondary Objective: Not applicable;Primary end point(s): disease progression or resectable tumor;Timepoint(s) of evaluation of this end point: Controll CT will be performed every 8-12 weeks to evaluate the eundpoints.	—

Measure

Time frame

Main Objective: Patient has inoperable pancretaic adenocarcinoma with ATM-P604S mutation. In case of alteration of ATM tumor suppressor gene, PARP inhibitors can be suitable for treatment. The aim of the treatment to shrink the tumor in order to make it removeable. ;Secondary Objective: Not applicable;Primary end point(s): disease progression or resectable tumor;Timepoint(s) of evaluation of this end point: Controll CT will be performed every 8-12 weeks to evaluate the eundpoints.

—

Secondary

Measure	Time frame
Secondary end point(s): Not applicale;Timepoint(s) of evaluation of this end point: Not applicable.	—

Countries

Hungary

Contacts

Public ContactAndrea Rochlitz

AbbVie Kft.

andrea.rochlitz@abbvie.com+36205658520

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026